A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors

Brief description of study

You may qualify for this study if you have metastatic or unresectable melanoma or other advanced solid tumors. This study will include three phases: a dose-escalation phase, dose-optimization phase, and dose-expansion. The investigational drug, SGN-BB228 is an antibody-anticalin fusion bispecific molecule that binds the co-stimulatory receptor 4-1BB and tumor antigen CD228, it may have the potential of delaying the development of metastatic lesions and/or controlling or reducing disease burden.

The study is being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken-down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on this medication during the entire study period.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.